Thursday was a day in which all stocks were getting bruised, including those in the health-care field. In New York, the sector got pummeled 1.1%, while in Canada, the sector suffered along with most other sectors, doffing 2.2%.
Tel Aviv-based Therapix Biosciences Ltd. (OTC:TRPXY), calling itself “a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments,” announced today that its American Depositary Shares (“ADSs”) will now trade under the OTC Pink ticker symbol “TRPXY.”
The company also announced the removal by an Israeli court of a previously reported temporary injunction against the Company prohibiting Therapix from making any changes in its share capital or adopting any resolution which is not in the ordinary course of business.
As of Wednesday, the company’s ADSs became eligible to trade on the OTC Pink Marketplace under the symbols “TRPXY.” Therapix previously announced that the listing of its ADSs was suspended by the NASDAQ Stock Market as of July 2.
TRPXY vaulted 7% to 20.61 cents, on volume of 403,000 shares.
From the other side of the behalf – and the “ounce of prevention” school, Toronto-based Quisitive Technology Solutions (TSX-Venture:QUIS) has thrown in its lot with Texas-based Inform Diagnostics, a leading U.S. commercial subspecialty anatomic pathology provider.
The two companies announced an agreement to expand their relationship to develop a real-time, biopsy tracking solution. This new collaboration will result in a mobile application powered by Microsoft Azure, Azure Artificial Intelligence (AI) and Microsoft Teams technologies. This purpose-built solution will provide clinicians with real-time information at their point of need.
Quisitive shares saw gains which were strong, though not necessarily hair-raising, of two cents, or 3.6%, to 58 cents, on volume of 106,000 shares.